BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 21, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2023

View Archived Issues
Mast cell releasing histamine during allergic response

Nervous system is unexpected player in anaphylactic shock

When undertaking a study on allergen-induced anaphylaxis in mice, researchers have found that not only the immune but also the nervous system may potentially play a part in the anaphylactic response. In their study published March 17, 2023, in Science Immunology, researchers from Duke University Medical Center reported that mice undergoing anaphylaxis displayed an “extended posture behavior” similar to the one that mice exhibit when exposed to high temperatures. Read More

Macrophages drive invasive breast cancer

T cells do not have the last word in some breast cancers. According to a study from the University of Pittsburgh, the key to estrogen receptor positive (ER+) breast tumors are macrophages, not T cells, and targeting them could prevent immunotherapy failure in this type of cancer. Read More
Brain and DNA

Quralis announces program targeting UNC13A mis-splicing for neurodegenerative diseases

Quralis Corp. has launched a program that targets UNC13A mis-splicing, a critical genetic alteration... Read More
Brain and encephalography

BHV-7000 demonstrates efficacy and safety in maximal electroshock seizure rat model

Researchers from Biohaven Pharmaceutical Holding Co. Ltd. presented preclinical data for... Read More

Novel compound heterozygous variant in EFL1 found in Shwachman-Diamond syndrome 2

Researchers from the University of Utah and collaborators presented data on a case report of... Read More
Vaccine vial and syringe

Cancervax's sponsored research program with UCLA on universal cancer vaccine now underway

Cancervax Inc.'s sponsored research program with the University of California Los Angeles (UCLA)... Read More

RP Scherer Technologies patents new antibody-drug conjugates for cancer

RP Scherer Technologies LLC has disclosed antibody-drug conjugates consisting of nectin-4... Read More
3D illustration of brain neuron in lysosomal storage diseases

Plasma lyso-sphingomyelin as biomarker of response to olipudase alfa in patients with ASMD

Acid sphingomyelinase deficiency (ASMD) is a progressive lysosomal storage disease caused by autosomal recessive pathogenic variants in the SMPD1 gene encoding acid sphingomyelinase (ASM). In a recent study, researchers from Albert Einstein College of Medicine aimed to assess the levels of plasma lyso-sphingomyelin, a deacylated form of sphingomyelin, in patients with ASMD pre- and post-treatment with olipudase alfa (recombinant-human acid sphingomyelinase). Read More

Reistone Biopharma divulges new MK2 inhibitors

Reistone Biopharma Co. Ltd. has synthesized quinolinofuran derivatives acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of fibrosis, autoimmune, inflammatory and metabolic disorders. Read More

Chinese researchers describe new dual antagonists of ETA and AT1 receptors

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified dual antagonists of endothelin ETA receptor and angiotensin AT1 receptor reported to be useful for the treatment of diabetes, hypertension and renal disorders. Read More
DNA-analysis-diagnostic-research.png

Investigators identify novel variants in the KIAA1109 gene related to Alkuraya-Kucinskas syndrome

Investigators from the Thomas Jefferson University have presented a case report of a 27-year-old pregnant patient in whom cystic hygroma, extensive anasarca, bilateral pleural effusions, ascites, abnormally curved sacrum and hydrocephalus with parenchymal volume loss, among others were detected by prenatal imaging during pregnancy (onset was at about 21 weeks of gestation). Read More

Impact Therapeutics presents new PARP inhibitors for cancer

Impact Therapeutics (Shanghai) Inc. has divulged substituted tricyclic compounds acting as poly(ADP-ribose) polymerase (PARP; ARTD) inhibitors reported to be useful for the treatment of cancer. Read More

Biofront discovers new HPK1 degradation inducers

Biofront Ltd. has described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) targeting moiety via linker acting as HPK1 degradation inducers reported to be useful for the treatment of cancer. Read More
neuron-network.png

Small-molecule activators of KCC2 reduce neuronal excitability, show efficacy in benzodiazepine-resistant status epilepticus

The neuron-specific K+/Cl- co-transporter KCC2 is involved in the shift from depolarizing to hyperpolarizing γ-aminobutyric acid receptor (GABAAR) currents and subsequent synaptic inhibition. Read More

Other news to note for March 20, 2023

Additional early-stage research and drug discovery news in brief, from: Escient Pharmaceuticals, Evgen Pharma, Ionctura, Propanc Biopharma. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing